Home > Insider Trading > Filing (0001325812-17-000038)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1178670	Alnylam Pharmaceuticals Inc.	ALKS	Pharmaceutical Preparations (2834)	770602661

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1620743	Laurie Keating	300 Third Street Cambridge MA 02142	Svp, Gc & Secretary	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2017-12-20	6,249	$42.22	17,749	No	4	M	Direct
Common Stock	Disposition	2017-12-20	4,049	$120.88	13,700	No	4	S	Direct
Common Stock	Disposition	2017-12-20	1,900	$121.67	11,800	No	4	S	Direct
Common Stock	Disposition	2017-12-20	300	$122.53	11,500	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Performance Based Stock Option 2016 (right to buy)	Acquisiton	2017-12-20	6,250	$0.00	6,250	$42.22
Common Stock	Stock Option (right to buy)	Disposition	2017-12-20	6,249	$0.00	6,249	$42.22

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
6,250	2017-12-20	2026-12-20	No	4	A	Direct
18,751		2026-12-20	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	257	Indirect	by Managed Account

Footnotes

All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2017.
Sale prices ranged from $120.45 to $121.40.
Sale prices ranged from $121.49 to $122.39.
Sale prices ranged from $122.51 to $122.58.
The reporting person owns 257 shares of ALNY common stock under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. Effective December 20, 2017, the compensation committee of the Company determined the first performance criterion had been met and the option vested as to one-quarter of the shares.
The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.